AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 111
- Registration Number
- NCT02127710
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Epidemiology of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Chronic Obstructive Pulmonary DiseaseChronic Bronchitis
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 976
- Registration Number
- NCT02128529
A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293
- First Posted Date
- 2014-04-30
- Last Posted Date
- 2014-06-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT02126514
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
- First Posted Date
- 2014-04-29
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 713
- Registration Number
- NCT02125461
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
OVArian Cancer Non-Interventional Study - OVATAR
Completed
- Conditions
- Ovarian, Peritoneal, Fallopian Tube Cancer, BRCAm+ in Russia
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 503
- Registration Number
- NCT02122588
- Locations
- 🇷🇺
Research Site, Vladimir, Russian Federation
Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients
Phase 4
Withdrawn
- Conditions
- Peripheral Artery DiseaseVascular DiseaseArterial Occlusion DiseaseIntermittent ClaudicationAnkle Brachial Index (0.9 or Less)
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02121288
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 953
- Registration Number
- NCT02104804
- Locations
- 🇨🇳
Research Site, Shiyan, China
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Phase 3
Completed
- Conditions
- Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
- Interventions
- Drug: Epanova® (omega-3 carboxylic acids)
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2021-08-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13078
- Registration Number
- NCT02104817
- Locations
- 🇬🇧
Research Site, Torquay, United Kingdom
Observational Prospective Study OPTIMA II - Follow-up
Completed
- Conditions
- Major Adverse Cardiovascular and Cerebrovascular Events (MACCE)
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 572
- Registration Number
- NCT02099565
- Locations
- 🇷🇺
Research Site, Moscow, Russian Federation
A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD)
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2014-03-31
- Last Posted Date
- 2016-12-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 860
- Registration Number
- NCT02100332